drugset / Trial / NCT00005595

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease

NCT00005595

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory Hodgkin's disease.

Timeline

Start
2000-06
Primary completion
2002-04
Completion
2002-04

Drugs

EvaluationDrugModalityDoseRoute
Subject arsenic trioxide Small molecule Intravenous

Indications